Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.410
-0.080 (-3.21%)
At close: Nov 20, 2024, 4:00 PM
2.550
+0.140 (5.81%)
Pre-market: Nov 21, 2024, 5:49 AM EST
Lipella Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.48 | 0.45 | 0.18 | 0.26 | 0.96 | 0.69 |
| Revenue Growth (YoY) | 0.78% | 144.15% | -28.99% | -73.03% | 38.42% | - |
| Cost of Revenue | 3.04 | 3.04 | 2.55 | 1.46 | 0.98 | 0.68 |
| Gross Profit | -2.56 | -2.59 | -2.36 | -1.2 | -0.01 | 0.01 |
| Selling, General & Admin | 1.84 | 2.16 | 0.23 | 0.72 | 0.04 | 0.07 |
| Operating Expenses | 1.8 | 2.16 | 0.23 | 0.72 | 0.04 | 0.07 |
| Operating Income | -4.36 | -4.75 | -2.59 | -1.92 | -0.06 | -0.05 |
| Interest Expense | - | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Interest & Investment Income | 0.1 | 0.14 | 0 | 0 | 0 | 0 |
| Other Non Operating Income (Expenses) | - | - | -0 | 0 | - | - |
| EBT Excluding Unusual Items | -4.26 | -4.62 | -2.6 | -1.92 | -0.06 | -0.06 |
| Other Unusual Items | - | - | - | 0.06 | - | - |
| Pretax Income | -4.26 | -4.62 | -2.6 | -1.87 | -0.06 | -0.06 |
| Net Income | -4.26 | -4.62 | -2.6 | -1.87 | -0.06 | -0.06 |
| Net Income to Common | -4.26 | -4.62 | -2.6 | -1.87 | -0.06 | -0.06 |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 | 0 |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 | 0 |
| Shares Change (YoY) | 41.54% | 47.84% | 19.15% | 59.91% | 2.46% | - |
| EPS (Basic) | -4.45 | -6.16 | -5.12 | -4.38 | -0.23 | -0.24 |
| EPS (Diluted) | -4.46 | -6.16 | -5.12 | -4.40 | -0.23 | -0.24 |
| Free Cash Flow | -3.69 | -3.16 | -1.83 | -0.99 | -0.03 | -0.04 |
| Free Cash Flow Per Share | -3.85 | -4.22 | -3.61 | -2.32 | -0.11 | -0.15 |
| Gross Margin | - | - | - | - | -1.48% | 1.71% |
| Operating Margin | -901.46% | -1055.55% | -1406.26% | -738.71% | -5.91% | -7.74% |
| Profit Margin | -881.73% | -1027.31% | -1410.59% | -719.30% | -6.41% | -8.90% |
| Free Cash Flow Margin | -762.73% | -703.84% | -994.35% | -381.45% | -2.97% | -5.63% |
| EBITDA | -4.36 | -4.74 | - | - | - | - |
| D&A For EBITDA | 0 | 0 | - | - | - | - |
| EBIT | -4.36 | -4.75 | -2.59 | -1.92 | -0.06 | -0.05 |
| EBIT Margin | - | - | - | - | -5.91% | -7.74% |
| Revenue as Reported | 0.48 | 0.45 | 0.18 | 0.26 | 0.96 | 0.69 |
Source: S&P Capital IQ. Standard template.
Financial Sources.